{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:34:06Z","timestamp":1773707646577,"version":"3.50.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005743","name":"Universit\u00e0 Cattolica del Sacro Cuore","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005743","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Intrathecal baclofen therapy (ITB) is a well-established treatment modality for severe spasticity, but it is burdened by the need for periodic pump refills. The introduction of a new formulation of baclofen with an extended stability of 180 days (Neteka, Nordic Group BV) could decrease the frequency of refills. We aimed at analyzing the clinical and economic impact of Neteka introduction in our outpatient facility.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Forty-eight patients with an implanted device for intrathecal baclofen infusion, who shifted from standard baclofen to Neteka, were included in the present study. We collected clinical and refilling data both from pre-Neteka and Neteka timeframes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In patients treated with baclofen 2\u00a0mg\/ml (45\/48, 93.8%), the introduction of Neteka led to a significant decrease of median number of refills per year (2.7 vs. 4 in pre-Neteka timeframe, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). This resulted in an improved quality of life, as shown by the reduction of Oberst Caregiving Burden Scale score both for time and difficulty of caregiving (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001 and <jats:italic>p<\/jats:italic>\u2009=\u20090.0003, respectively). Furthermore, a median saving of 302.40 euro per year per patient, as compared to pre-Neteka timeframe, was registered. Similar results were obtained in the smaller cohort treated with baclofen 0.5\u00a0mg\/ml (3\/48, 6.3%). Neteka appreciation rate was high. As expected, no changes in clinical effectiveness of ITB therapy were observed by comparing pre-Neteka and Neteka timeframes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The extended half-life provided by Neteka, by reducing the number of refills, could improve patient quality of life, enhance caregiver satisfaction, and decrease the financial burden on healthcare system.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s10072-024-07965-z","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T07:06:34Z","timestamp":1736751994000},"page":"2229-2234","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-world impact of intrathecal baclofen therapy: the benefits of neteka on patient outcomes, caregiver burden, and cost efficiency"],"prefix":"10.1007","volume":"46","author":[{"given":"Manuela","family":"D\u2019Ercole","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetta","family":"Burattini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2953-9291","authenticated-orcid":false,"given":"Quintino Giorgio","family":"D\u2019Alessandris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Filomena","family":"Fuggetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Pambianco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Annunziata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Izzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Montano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"key":"7965_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.11622\/smedj.2016005","volume":"57","author":"ZM Wang","year":"2016","unstructured":"Wang ZM, Law JH, King NKK et al (2016) Treatment of severe, disabling spasticity with continuous intrathecal baclofen therapy following acquired brain injury: the experience of a tertiary institution in Singapore. Singap Med J 57:8\u201312. https:\/\/doi.org\/10.11622\/smedj.2016005","journal-title":"Singap Med J"},{"key":"7965_CR2","doi-asserted-by":"publisher","first-page":"e908","DOI":"10.1016\/j.wneu.2024.05.009","volume":"187","author":"N Medawar","year":"2024","unstructured":"Medawar N, Abdallah R, Kobaiter Maarrawi S, Maarrawi J (2024) Intrathecal Baclofen Therapy for Refractory spasticity: a Case Series. World Neurosurg 187:e908\u2013e913. https:\/\/doi.org\/10.1016\/j.wneu.2024.05.009","journal-title":"World Neurosurg"},{"key":"7965_CR3","doi-asserted-by":"publisher","first-page":"605","DOI":"10.23736\/S0390-5616.21.05410-2","volume":"67","author":"M D\u2019Ercole","year":"2023","unstructured":"D\u2019Ercole M, Izzo A, Fuggetta F et al (2023) The impact of strategies to manage the COVID-19 pandemic on patients with intrathecal baclofen therapy. J Neurosurg Sci 67:605\u2013608. https:\/\/doi.org\/10.23736\/S0390-5616.21.05410-2","journal-title":"J Neurosurg Sci"},{"key":"7965_CR4","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.neurom.2023.01.017","volume":"26","author":"V Venkatraman","year":"2023","unstructured":"Venkatraman V, Spears CA, Futch BG et al (2023) Assessment of Health Care costs and total Baclofen Use Associated with targeted drug delivery for spasticity. Neuromodulation 26:1247\u20131255. https:\/\/doi.org\/10.1016\/j.neurom.2023.01.017","journal-title":"Neuromodulation"},{"key":"7965_CR5","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/ner.12388","volume":"19","author":"AL Boster","year":"2016","unstructured":"Boster AL, Adair RL, Gooch JL et al (2016) Best practices for Intrathecal Baclofen Therapy: Dosing and Long-Term Management. Neuromodulation 19:623\u2013631. https:\/\/doi.org\/10.1111\/ner.12388","journal-title":"Neuromodulation"},{"key":"7965_CR6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/01376517-200404000-00007","volume":"36","author":"T Bakas","year":"2004","unstructured":"Bakas T, Austin JK, Jessup SL et al (2004) Time and difficulty of tasks provided by family caregivers of stroke survivors. J Neurosci Nurs 36:95\u2013106. https:\/\/doi.org\/10.1097\/01376517-200404000-00007","journal-title":"J Neurosci Nurs"},{"key":"7965_CR7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.toxicon.2012.11.025","volume":"67","author":"A Esquenazi","year":"2013","unstructured":"Esquenazi A, Albanese A, Chancellor MB et al (2013) Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome. Toxicon 67:115\u2013128. https:\/\/doi.org\/10.1016\/j.toxicon.2012.11.025","journal-title":"Toxicon"},{"key":"7965_CR8","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.pmrj.2017.08.441","volume":"10","author":"MJ McLaughlin","year":"2018","unstructured":"McLaughlin MJ, He Y, Brunstrom-Hernandez J et al (2018) Pharmacogenomic variability of oral Baclofen Clearance and Clinical Response in Children with cerebral palsy. PM R 10:235\u2013243. https:\/\/doi.org\/10.1016\/j.pmrj.2017.08.441","journal-title":"PM R"},{"key":"7965_CR9","first-page":"131","volume":"40","author":"GE Francisco","year":"2004","unstructured":"Francisco GE (2004) The role of intrathecal baclofen therapy in the upper motor neuron syndrome. Eura Medicophys 40:131\u2013143","journal-title":"Eura Medicophys"},{"key":"7965_CR10","doi-asserted-by":"publisher","unstructured":"G\u00fcnd\u00fcz ME, Haak F, Visser-Vandewalle V, Matis G (2023) Dose escalation in intrathecal baclofen therapy based on disease etiology: can an a priori target dose be established? A ten-year follow-up study. J Spinal Cord Med 1\u20137. https:\/\/doi.org\/10.1080\/10790268.2023.2266614","DOI":"10.1080\/10790268.2023.2266614"},{"key":"7965_CR11","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1016\/j.apmr.2009.05.018","volume":"90","author":"E Moberg-Wolff","year":"2009","unstructured":"Moberg-Wolff E (2009) Potential clinical impact of compounded versus noncompounded intrathecal baclofen. Arch Phys Med Rehabil 90:1815\u20131820. https:\/\/doi.org\/10.1016\/j.apmr.2009.05.018","journal-title":"Arch Phys Med Rehabil"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07965-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-024-07965-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07965-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T11:56:58Z","timestamp":1744804618000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-024-07965-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":11,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["7965"],"URL":"https:\/\/doi.org\/10.1007\/s10072-024-07965-z","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,13]]},"assertion":[{"value":"7 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Research involving human participants and\/or animals: The study was conducted according to the principles set forth in the Declaration of Helsinki. This is a \u201ccurrent research\u201d study under Italian law not requiring formal approval by Institutional Ethics Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}